Search Results for "allergy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for allergy. Results 141 to 150 of 200 total matches.

New Advertisement for An Old Antihistamine

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 1993  (Issue 888)
) and possibly other drugs that inhibit hepatic metabolism (Medical Letter, 34:9, 1992; FER Simons, Ann Allergy ...
Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.
Med Lett Drugs Ther. 1993 Jan 22;35(888):9-10 |  Show IntroductionHide Introduction

Edaravone (Radicava) for ALS

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 2017  (Issue 1533)
contains sodium bisulfite, which can cause hypersensitivity reactions in patients with sulfite allergy ...
The FDA has approved edaravone (Radicava – Mitsubishi Tanabe Pharma) for treatment of amyotrophic lateral sclerosis (ALS). It is the second drug to be approved in the US for this indication; riluzole (Rilutek, and generics) was approved in 1995. Edaravone was approved for treatment of ALS as Radicut in Japan and South Korea in 2015. It has been used in Japan and other Asian countries since 2001 for treatment of acute ischemic stroke.
Med Lett Drugs Ther. 2017 Nov 6;59(1533):180-2 |  Show IntroductionHide Introduction

Roflumilast Cream (Zoryve) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
in) adulthood. AD is frequently associated with food allergies, allergic rhinitis, and asthma. TOPICAL ...
The FDA has approved a 0.15% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of mild to moderate atopic dermatitis (AD) in patients ≥6 years old. Roflumilast is the second PDE4 inhibitor to be approved in the US for treatment of AD; crisaborole (Eucrisa), which can be used in patients ≥3 months old, was the first. Roflumilast is available as Zoryve in a 0.3% cream for treatment of plaque psoriasis and a 0.3% foam for treatment of seborrheic dermatitis. It is also available in an oral formulation (Daliresp) for...
Med Lett Drugs Ther. 2024 Sep 16;66(1711):150-1   doi:10.58347/tml.2024.1711b |  Show IntroductionHide Introduction

Onapgo — An Apomorphine Subcutaneous Infusion for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
in patients with a sulfite allergy. DRUG INTERACTIONS ― Dopamine antagonists such as prochlorperazine ...
Onapgo (Supernus), a solution for continuous subcutaneous infusion containing the dopamine agonist apomorphine, has been approved by the FDA for treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Subcutaneously injected apomorphine (Apokyn, and generics) has been available for intermittent use for years. Vyalev, a foscarbidopa/foslevodopa solution for subcutaneous infusion, was approved in 2024 for the same indication.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):116-8   doi:10.58347/tml.2025.1733d |  Show IntroductionHide Introduction

Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
in) adulthood. It is frequently associated with food allergies, allergic rhinitis, and asthma.5 SYSTEMIC ...
The subcutaneously injected interleukin-13 (IL-13) antagonist tralokinumab-ldrm (Adbry – Leo) and the oral Janus kinase (JAK) inhibitors abrocitinib (Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie) have been approved by the FDA for treatment of moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5   doi:10.58347/tml.2023.1673b |  Show IntroductionHide Introduction

Desk-Top Systems For Office Chemistries

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990  (Issue 829)
, Ther Drug Monitoring, 11:73, 1989), theophylline (P Singh, Ann Allergy, 59:176, 1987), triglycerides ...
Four different desk-top systems are now widely used in physicians'; offices to measure blood chemistries. The Ektachem DT (Kodak) and Reflotron (Boehringer Mannheim), reviewed previously in The Medical Letter (volume 30, page 119, 1988; volume 31, page 90, 1989), resemble the Seralyzer (Miles Diagnostics) in cost; the Vision (Abbott), which is fully automated, is much more expensive.
Med Lett Drugs Ther. 1990 Oct 19;32(829):96-8 |  Show IntroductionHide Introduction

Rimantadine for Prevention and Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • Nov 26, 1993  (Issue 910)
if influenza vaccine cannot be given because of allergy, if the epidemic strain differs from the antigens ...
Rimantadine hydrochloride (Flumadine - Forest), the alpha-methyl derivative of amantadine (Symmetrel, and others), was recently approved by the US Food and Drug Administration for prevention and treatment of influenza A virus infections in adults and for prevention of influenza in children.
Med Lett Drugs Ther. 1993 Nov 26;35(910):109-10 |  Show IntroductionHide Introduction

Formoterol (Foradil Aerolizer) For Asthma

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
symptom scores (G Bensch et al, Ann Allergy Asthma Immunol 2001; 86:19). Concurrent use of formoterol ...
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
Med Lett Drugs Ther. 2001 May 14;43(1104):39-40 |  Show IntroductionHide Introduction

Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018  (Issue 1541)
Allergy Organ J 2012; 5:182. 3. BL Zuraw et al. Nanofiltered C1 inhibitor concentrate for treatment ...
The FDA has approved Haegarda (CSL Bering), a human plasma-derived C1 esterase inhibitor (C1INH), for prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults. Haegarda is the fourth C1INH to be approved by the FDA and the second to be approved for HAE prophylaxis. Unlike the other C1INHs, Haegarda is self-administered subcutaneously rather than intravenously.
Med Lett Drugs Ther. 2018 Feb 26;60(1541):39-40 |  Show IntroductionHide Introduction

Drugs for Pneumonia

   
Treatment Guidelines from The Medical Letter • Sep 01, 2003  (Issue 13)
allergy will also develop allergic reactions to a cephalosporin; no skin testing materials are available ...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Treat Guidel Med Lett. 2003 Sep;1(13):83-8 |  Show IntroductionHide Introduction